Ireland’s National Cancer Control Programme (NCCP) has issued new guidance on the use of biosimilar medicines in the treatment of cancer.
Ireland’s National Cancer Control Programme (NCCP) has issued new guidance on the use of biosimilar medicines in the treatment of cancer.
The guidance includes recommendations on 4 areas of concern with biosimilar products:
The NCCP’s guidance also indicates that, in Ireland, substitution of biosimilars by pharmacists is not currently provided for under the law. Therefore, any change between a reference product and a biosimilar must involve the prescribing physician.
The NCCP says that it welcomes the introduction of biosimilars into the Irish healthcare marketplace, and that biosimilars represent a way to “obtain sustainability and [maximize] the funding for new medicines to be made available for patient treatment.”
Ireland has already undertaken work to address the cost of biologic medications in order to make cancer treatment more sustainable; its 2016 Framework Agreement on the Supply and Pricing of Medicines, an agreement between the pharmaceutical industry and the government, held that the price the government’s health system pays for a biologic treatment that loses patent protection after August 1, 2016 must drop to 80% of its July 31, 2016 price. The government also requires that manufacturers make available an additional rebate of 12.5% on such reference biologics.
Ireland’s Minister for Health has also recently published a consultation paper on the nation’s approach to biosimilar treatments in order to encourage wider use of cost-saving drugs. Despite the fact that 11 biosimilars are currently reimbursable by the state’s health system, Ireland has one of the lowest biosimilar adoption levels in Europe. The government will receive public comments on the paper, which calls for the exploration of a variety of potential policies to encourage biosimilar uptake, until September 22, 2017.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.